DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0189680 A1 Keown Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 201101.89680A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0189680 A1 KeoWn et al. (43) Pub. Date: Aug. 4, 2011 (54) METHODS OF DIAGNOSING REJECTION OF Related U.S. Application Data A KIDNEY ALLOGRAFT USING GENOMIC (60) Provisional application No. 61/129,022, filed on May OR PROTEOMC EXPRESSION PROFILNG 30, 2008. Publication Classification (75) Inventors: Paul Keown, Delta (CA); Andreas (51) Int. Cl. Scherer, Kontiolahti (FI): Oliver CI2O I/68 (2006.01) Gunther, Vancouver (CA); Robert GOIN 33/53 (2006.01) Balshaw, Vancouver (CA); GOIN 33/68 (2006.01) Raymond Ng, Vancouver (CA); CI2O 1/48 (2006.01) Alice Mui, Burnaby (CA); Robert CI2O I/00 (2006.01) McMaster, Vancouver (CA); Bruce CI2O I/37 (2006.01) McManus, Vancouver (CA); GOIN 33/573 (2006.01) Gabriela Cohen Freue, Vancouver HOIJ 49/26 (2006.01) (CA); Anna Meredith, Vancouver (52) U.S. Cl. ............ 435/6.12: 436/94; 436/86; 436/501; (CA) 435/7.92; 435/15; 435/4; 435/23: 435/7.4: 250/282 (73) Assignee: The University of British (57) ABSTRACT Columbia, Vancouver, BC (CA) A method of determining the acute allograft rejection status of a subject, the method comprising the steps of determining (21) Appl. No.: 12/991,922 the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the Subject; comparing (22) PCT Filed: May 29, 2009 the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the (86). PCT No.: PCTACA2O09/OOOT44 expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein S371 (c)(1), the increase of the one or more than one nucleic acid markers (2), (4) Date: Mar. 15, 2011 is indicative of the acute rejection status of the subject. Patent Application Publication Aug. 4, 2011 Sheet 1 of 31 US 2011/0189680 A1 Figure 1A w O -O- BCAR - C - Controls cy) o - c\ O v c t d -- C -200 -100 O 1OO 200 300 400 Linear Discriminant SCOre Figure 1B w cs I, : -o- BCAR - C - Controls ; : - NS : dw | st raiso, H. mains a -222 -218 -214 -210 426 430 434 438 Linear Discriminant Score Linear Discriminant Score Patent Application Publication Aug. 4, 2011 Sheet 2 of 31 US 2011/O189680 A1 Figure 1C 5 fore 5 i 300-200-100 0 100 200 300 400 500 Discriminant war. 1 Patent Application Publication Aug. 4, 2011 Sheet 3 of 31 US 2011/O189680 A1 Figure 2 N 5 www. S 2.5 O 8 0. 0. O O -2.5 {0 -5 --- -3 -1 1 3 Discriminant War. 1 0 Acute Rejection O No Rejection Patent Application Publication Aug. 4, 2011 Sheet 4 of 31 US 2011/O189680 A1 Figure 3 Og foid-change Patent Application Publication Aug. 4, 2011 Sheet 5 of 31 US 2011/O189680 A1 Figure 4 10 -10 -28 -24 -20 - 16 -12 -8 56% 8 12 16 20 24, 28 Patent Application Publication Aug. 4, 2011 Sheet 6 of 31 US 2011/O189680 A1 Figure 5A actin cytoskeletor organization and biogenesis cytoskeleton organization and biogenesis actr; filarret-based process irrirrture systern process positive regulation of irrtune system process ce activation eukocyte activation response to bacterium regulation of protein retabolic process | protein kinase cascade positive regulation of response to stirrus actin filament organization cell motility localization of ce. regulation of irrirune systern process : regulation of cellular protein retabolic process signal transduction regation of response to simulus regulation of epiderral growth factor receptor activity regulation af receptor activity is i Figure 5B Cytoskeeter. Atif farerts Cytoskeleton_Regulation of cytoskeleton. infarrirration jak-SA Pathway it rephagocytosis riarratior Enterferor sigraig 3 8 Ce adhesioi etcote citerrotaxis Cell adhesior Gircoconjugates reproduction feedirig and era horrores sigFairg 8 : Celadhesior Arryloid proteins : : Proliferatior y rr photcyte proferation : exeoprent terror oiesis, Erythropoietir pathway : irtfar ratif -2 signerg : irrurie Phagosore in antiger presentation : Celadhesio regrin prinrirg : rarsatioregatio of iritiation Signal trarseiuctioS2 pathway Sigrial trarsdiction ESri-rticlear pathway Ce adhesior integrif-prediated ceil-rratrix acresion Cardiac developresert FGF Era sigrating ap optosis beath sorrain recepters & aspases if... Patent Application Publication Aug. 4, 2011 Sheet 7 of 31 US 2011/O189680 A1 Figure 6A 3 - | 5: g/ -- I - - I I I : : t Figure 6B 5 O 5 O Linear Discriminant Score Figure 6C : - BCAR K - or - no BCAR W 2 N - / \ s \ } : f : - - - d o Ho-3. ... 3 3- r : -T T I I B. W1 W2. W3 WA W2 Patent Application Publication Aug. 4, 2011 Sheet 8 of 31 US 2011/O189680 A1 Figure 7 KP3: 11 ARVS 21 NR O w - cyd - an O 9. (s > O) O 8 o 86°GO 0 O - t -0.4 -0.2 0.0 0.2 0.4 Log mean fold-change Patent Application Publication Aug. 4, 2011 Sheet 9 of 31 US 2011/O189680 A1 Figure 8 ---- BPAR Controls S3 s Linear Discriminant Wariable Figure 9 c - - - - - - - - - - - - - - - w 8 S. S START 111 224 23 18 100 116 38 135 125 PGC US 2011/O 189680 A1 Aug. 4, 2011 METHODS OF DAGNOSING REUECTION OF ~6-12 months of the subject receiving the allograft. Rejection A KIDNEY ALLOGRAFT USING GENOMIC or acute rejection may be characterized by cellular and OR PROTEOMC EXPRESSION PROFILNG humoral insults on the donor tissue, leading to rapid graft dysfunction and failure of the tissue or organ. Rejection of a tissue or organ allograft beyond 6-12 months is generally 0001. This application claims priority benefit of U.S. Pro considered to be chronic rejection, and may occur several visional application 61/129,022, filed May 30, 2008, the con years after receiving the allograft. Such late or chronic rejec tents of which is herein incorporated by reference. tion may be the result of sub-clinical or not fully resolved acute rejection episodes. Later-onset or chronic rejection may FIELD OF INVENTION be characterized by progressive tissue remodeling triggered 0002 The present invention relates to methods of diagnos by the alloimmune response may lead to gradual neointimal ing rejection of a kidney allograft using genomic expression formation within arteries, contributing to obliterative vascu profiling or proteomic expression profiling. lopathy, parenchymal fibrosis and consequently, failure and loss of the graft. Depending on the nature and severity of the BACKGROUND OF THE INVENTION rejection, there may be overlap in the indicators or clinical variables observed in a Subject undergoing, or Suspected of 0003 Transplantation is considered the primary therapy undergoing, allograft rejection—either chronic or acute. for patients with end-stage vital organ failure. While the avail 0008. The scientific and patent literature is blessed with ability of immunosuppressants such as cyclosporine and tac reports of this marker or that being important for identifica rolimus has improved allograft recipient survival and wellbe tion/diagnosis/prediction/treatment of every medical condi ing, identification of rejection of the allograft as early and as tion that can be named. Even within the field of allograft accurately as possible, and effective monitoring and adjusting rejection, a myriad of markers are recited (frequently singly), immunosuppressive medication doses is still of primary and conflicting results may be presented. This conflict in the importance to the continuing Survival of the allograft recipi literature, added to the complexity of the genome (estimates ent. range upwards of 30,000 transcriptional units), the variety of 0004 Rejection of an allograft results from a recipient's cell types (estimates range upwards of 200), organs and tis immune response to nonself antigens expressed by the donor Sues, and expressed proteins or polypeptides (estimates range tissues, and may occur with hours or days of receiving the upwards of 80,000) in the human body, renders the number of allograft, or months to years later. Renal allograft rejection is possible nucleic acid sequences, genes, proteins, metabolites characterized by features comprising oliguria, rapid deterio or combinations thereof useful for diagnosing acute organ ration of renal function and mild proteinuria. Renal allograft rejection is staggering. Variation between individuals pre rejection can lead to nephropathy and kidney failure. sents additional obstacles, as well as the dynamic range of 0005. At present, invasive biopsies (e.g. endomyocardial, protein concentration in plasma (ranging from 10 to 10 liver core, and renal fine-needle aspiration) are regarded as ug/mL) with many of the proteins of potential interest exist the gold standard for the Surveillance and diagnosis of ing at very low concentrations) and the overwhelming quan allograft rejections, but are invasive procedures which carry tities of the few, most abundant plasma proteins (constituting risks of their own (e.g. Mehra MR, et al. Curr. Opin. Cardiol. ~99% of the total protein mass. 2002 March; 17(2): 131-136.). Biopsy results may also be 0009 PCT Publication WO 2006/125301 discloses Subject to reproducibility and interpretation issues due to nucleic acids that are differentially expressed in transplanted sampling errors and inter-observer variabilities, despite the tissue, and methods and materials for detecting kidney tissue availability of international guidelines such as the Banff rejection. schema for grading kidney and liver allograft rejection (Solez et al 2008 Am J Transplant 8: 753: Table 1) An allograft (0010 U.S. Pat. No. 7,235,258 discloses methods of diag recipient may be exposed to the biopsy procedure multiple nosing or monitoring transplant rejection, including kidney times in the first year following the transplant. Noninvasive transplant rejection in a Subject, by detecting the expression Surveillance techniques are currently used (the increase in level of one or more genes in the Subject.
Recommended publications
  • Nutrigenomics in Human Peripheral Blood Mononuclear Cells

    Nutrigenomics in Human Peripheral Blood Mononuclear Cells

    Nutrigenomics in human peripheral blood mononuclear cells The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Mark Bouwens Promotor Prof. dr. Michael R. Müller Hoogleraar Voeding, Metabolisme en Genomics Afdeling Humane Voeding, Wageningen Universiteit Co-promotor Dr. ir. Lydia A. Afman Universitair docent Afdeling Humane Voeding, Wageningen Universiteit Promotiecommissie Prof. dr. Hannelore Daniel Technical University of Munich, Germany Dr. ir. Baukje de Roos Rowett Research Institute, Scotland Prof. dr. ir. Wim H.M. Saris Universiteit Maastricht Prof. dr. Huub F.J. Savelkoul Wageningen Universiteit Dit onderzoek is uitgevoerd binnen de onderzoeksschool VLAG (Voeding, Levensmiddelentechnologie, Agrobiotechnologie en Gezondheid) Nutrigenomics in human peripheral blood mononuclear cells The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Mark Bouwens Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof. dr. M.J. Kropff, in het openbaar te verdedigen op vrijdag 20 februari 2009 des namiddags te half twee in de Aula. Mark Bouwens Nutrigenomics in human peripheral blood mononuclear cells. The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies Thesis Wageningen University, Wageningen, the Netherlands, 2009. With abstract – with references – with summary in Dutch. ISBN: 978-90-8585-327-5 Abstract Nutrigenomics in human peripheral blood mononuclear cells. The effects of fatty acids on gene expression profiles of human circulating cells as assessed in human intervention studies PhD thesis by Mark Bouwens, Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands, February 20, 2009 Peripheral blood mononuclear cells (PBMCs) are circulating immune cells.
  • WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT

    WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2010/129023 A9 11 November 2010 (11.11.2010) PCT (51) International Patent Classification: (74) Agent: BAKER, C , Hunter; Wolf, Greenfield & Sacks, C07K 14/00 (2006.01) P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (21) International Application Number: PCT/US20 10/00 1250 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 28 April 2010 (28.04.2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Langi English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/173,430 28 April 2009 (28.04.2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 61/321,428 6 April 2010 (06.04.2010) US SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): PRESI¬ DENT AND FELLOWS OF HARVARD COLLEGE (84) Designated States (unless otherwise indicated, for every [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0304845 A1 Loboda Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0304845 A1 Loboda Et Al

    US 201403.04845A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0304845 A1 Loboda et al. (43) Pub. Date: Oct. 9, 2014 54) ALZHEMIERS DISEASE SIGNATURE Publicationublication ClassificatiClassification MARKERS AND METHODS OF USE (51) Int. Cl. (71) Applicant: MERCKSHARP & DOHME CORP, CI2O I/68 (2006.01) Rahway, NJ (US) AOIK 67/027 (2006.01) (52) U.S. Cl. (72) Inventors: SIES yet.sS); CPC .......... CI2O I/6883 (2013.01); A0IK 67/0275 Icnaei NepoZnyn, Yeadon, (2013.01) le.East,Italia; David J. Stone, Wyncote, USPC .............. 800/12:536/23.5:536/23.2:506/17 (US); Keith Tanis, Quakertown, PA (US); William J. Ray, Juniper, FL (US) (57) ABSTRACT (21) Appl. No.: 14/354,622 Methods, biomarkers, and expression signatures are dis 1-1. closed for assessing the disease progression of Alzheimer's (22) PCT Filed: Oct. 26, 2012 disease (AD). In one embodiment, BioAge (biological age), NdStress (neurodegenerative stress), Alz (Alzheimer), and (86). PCT No.: PCT/US12A62218 Inflame (inflammation) are used as biomarkers of AD pro S371 (c)(1), gression. In another aspect, the invention comprises a gene (2), (4) Date: Apr. 28, 2014 signature for evaluating disease progression. In still another Related U.S. Application Data abiliticises in (60) Provisional application No. 61/553,400, filed on Oct. used to identify animal models for use in the development and 31, 2011. evaluation of therapeutics for the treatment of AD. Patent Application Publication Oct. 9, 2014 Sheet 1 of 16 US 2014/0304845 A1 Y : : O O O O O O O O D O v v CN On cy Patent Application Publication Oct.
  • Supp Table 6.Pdf

    Supp Table 6.Pdf

    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T

    WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • Qt38n028mr Nosplash A3e1d84

    Qt38n028mr Nosplash A3e1d84

    ! ""! ACKNOWLEDGEMENTS I dedicate this thesis to my parents who inspired me to become a scientist through invigorating scientific discussions at the dinner table even when I was too young to understand what the hippocampus was. They also prepared me for the ups and downs of science and supported me through all of these experiences. I would like to thank my advisor Dr. Elizabeth Blackburn and my thesis committee members Dr. Eric Verdin, and Dr. Emmanuelle Passegue. Liz created a nurturing and supportive environment for me to explore my own ideas, while at the same time teaching me how to love science, test my questions, and of course provide endless ways to think about telomeres and telomerase. Eric and Emmanuelle both gave specific critical advice about the proper experiments for T cells and both volunteered their lab members for further critical advice. I always felt inspired with a sense of direction after thesis committee meetings. The Blackburn lab is full of smart and dedicated scientists whom I am thankful for their support. Specifically Dr. Shang Li and Dr. Brad Stohr for their stimulating scientific debates and “arguments.” Dr. Jue Lin, Dana Smith, Kyle Lapham, Dr. Tet Matsuguchi, and Kyle Jay for their friendships and discussions about what my data could possibly mean. Dr. Eva Samal for teaching me molecular biology techniques and putting up with my late night lab exercises. Beth Cimini for her expertise with microscopy, FACs, singing, and most of all for being a caring and supportive friend. Finally, I would like to thank Dr. Imke Listerman, my scientific partner for most of the breast cancer experiments.
  • Estudo De Associação Genética Em Larga Escala Identifica Potenciais Regiões Candidatas Para O Bruxismo Do Sono

    Estudo De Associação Genética Em Larga Escala Identifica Potenciais Regiões Candidatas Para O Bruxismo Do Sono

    Rosalvo Amaral Junior Estudo de associação genética em larga escala identifica potenciais regiões candidatas para o bruxismo do sono Dissertação apresentada à Universidade Federal de São Paulo – Escola Paulista de Medicina, para obtenção do Título de Mestre em Ciências São Paulo 2017 Rosalvo Amaral Junior Estudo de associação genética em larga escala identifica potenciais regiões candidatas para o bruxismo do sono Dissertação apresentada à Universidade Federal de São Paulo – Escola Paulista de Medicina, para obtenção do Título de Mestre em Ciências Orientadora: Profa. Dra. Monica Levy Andersen Coorientadora: Dra. Camila Hirotsu São Paulo 2017 Amaral Junior, Rosalvo Estudo de associação genética em larga escala identifica potenciais regiões candidatas para o bruxismo do sono/ Rosalvo Amaral Junior. São Paulo, 2017. xxiii, 100f. Dissertação (Mestrado) – Universidade Federal de São Paulo. Escola Paulista de Medicina. Programa de Pós -graduação em Psicobiologia. Título em inglês: Genome-wide association study identifies potential candidate gene regions for sleep bruxism. 1. Bruxismo do sono. 2. Genética. 3. Polimorfismo. 4. Polissonografia. Rosalvo Amaral Junior UNIVERSIDADE FEDERAL DE SÃO PAULO ESCOLA PAULISTA DE MEDICINA DEPARTAMENTO DE PSICOBIOLOGIA Chefe do Departamento: Prof. Dr. José Carlos Fernandes Galduróz Coordenadora do Curso de Pós-graduação: Profa. Dra. Débora Cristina Hipólide iii Rosalvo Amaral Junior Estudo de associação genética em larga escala identifica potenciais regiões candidatas para o bruxismo do sono Presidente da
  • Potential Role Vasculogenesis in Lupus Are Mediated

    Potential Role Vasculogenesis in Lupus Are Mediated

    Downloaded from http://www.jimmunol.org/ by guest on September 28, 2021 Kaplan is online at: on α average * The Journal of Immunology published online 30 August 2010 from submission to initial decision 4 weeks from acceptance to publication The Detrimental Effects of IFN- http://www.jimmunol.org/content/early/2010/08/30/jimmun ol.1001782 Vasculogenesis in Lupus Are Mediated by Repression of IL-1 Pathways: Potential Role in Atherogenesis and Renal Vascular Rarefaction J Immunol Seth G. Thacker, Celine C. Berthier, Deborah Mattinzoli, Maria Pia Rastaldi, Matthias Kretzler and Mariana J. Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2010/08/30/jimmunol.100178 2.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 28, 2021. Published August 30, 2010, doi:10.4049/jimmunol.1001782 The Journal of Immunology The Detrimental Effects of IFN-a on Vasculogenesis in Lupus Are Mediated by Repression of IL-1 Pathways: Potential Role in Atherogenesis and Renal Vascular Rarefaction Seth G. Thacker,*,1 Celine C. Berthier,†,1 Deborah Mattinzoli,‡ Maria Pia Rastaldi,‡ Matthias Kretzler,† and Mariana J.
  • Interrogating ARDS Risk and Severity Utilizing Genomic and Systems Biology Approaches

    Interrogating ARDS Risk and Severity Utilizing Genomic and Systems Biology Approaches

    Interrogating ARDS Risk and Severity Utilizing Genomic and Systems Biology Approaches Item Type text; Electronic Dissertation Authors Lynn, Heather D. Citation Lynn, Heather D. (2020). Interrogating ARDS Risk and Severity Utilizing Genomic and Systems Biology Approaches (Doctoral dissertation, University of Arizona, Tucson, USA). Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction, presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 07/10/2021 14:43:39 Link to Item http://hdl.handle.net/10150/650808 INTERROGATING ARDS RISK AND SEVERITY UTILIZING GENOMIC AND SYSTEMS BIOLOGY APPROACHES by Heather Lynn _________________________ Copyright © Heather Lynn 2020 A Dissertation Submitted to the Faculty of the GRADUATE INTERDISCIPLINARY PROGRAM IN PHYSIOLOGICAL SCIENCES In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2020 Acknowledgements & Dedications Many people’s efforts and time besides my own went into the creation and refinement of this work. I would first like to acknowledge my mentor, Dr. Garcia, without whose support none of this would be possible. Secondly, I want to acknowledge my committee members (Drs Coletta, Karnes, Ledford, and Sun) that have contributed to both the scientific aspects of this thesis and to the personal task of mentoring and teaching me their own areas of expertise they brought to this project. Third, I would like to thank the support of the many professors and staff of the Physiological Sciences GIDP for financial, logistical, and intellectual support during graduate school.
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression

    1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression

    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
  • Adrenomedullin and Receptor for Urokinase Plasminogen Activator Are Involved

    Adrenomedullin and Receptor for Urokinase Plasminogen Activator Are Involved

    Adrenomedullin and Receptor for Urokinase Plasminogen Activator are involved in Hereditary Angioedema attacks: a transcriptomic study Giuseppe Castellano*1, Chiara Divella*1, Fabio Sallustio*1, Vincenzo Montinaro1, Claudia Curci1, Andrea Zanichelli2, Erika Bonanni2, Chiara Suffritti2, Sonia Caccia2, Anna Gallone3, Francesco Paolo Schena4, Loreto Gesualdo MD1, Marco Cicardi2 (1) Nephrology Unit ; Department of Emergency and Organ Transplantation, University “Aldo Moro” Bari, Italy, and Center for Diagnosis and Treatment of Hereditary Angioedema. (2) Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy. (3) Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, 70124, Italy. (4) University of Bari and Fondazione Schena, Valenzano, Bari, Italy. Corresponding author: Giuseppe Castellano, M.D., PhD; Nephrology Unit ; Department of Emergency and Organ Transplantation, University “Aldo Moro” Bari, Italy, and Center for Diagnosis and Treatment of Hereditary Angioedema. Piazza G. Cesare,11 70124 Bari, Italy; Tel./Fax : 0039 080 5478878; Email: [email protected] * Giuseppe Castellano and Chiara Divella and Fabio Sallustio equally contributed to the present study. Loreto Gesualdo, Francesco Paolo Schena and Marco Cicardi shared senior authorship Acknowledgments 1 Supported by The Telethon Foundation (Telethon Grant number: GGP08223 granted to GC, SC and MC). Disclosure of potential conflict of interest The rest of the authors declare that they have no relevant conflicts of interest. 2 Abstract Background: Hereditary Angioedema (HAE) due to C1-inhibitor deficiency is a lifelong illness characterized by recurrent acute attacks of localized skin or mucosal edema. An activation of the kallikrein/bradykinin pathway at endothelial cell level has a relevant pathogenetic role in acute HAE attacks.
  • WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T

    WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/095793 Al 27 June 2013 (27.06.2013) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/063579 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 5 November 20 12 (05 .11.20 12) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/579,530 22 December 201 1 (22. 12.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: AVEO PHARMACEUTICALS, INC. kind of regional protection available): ARIPO (BW, GH, [US/US]; 75 Sidney Street, Fourth Floor, Cambridge, MA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 02139 (US).